DelveInsight’s, “BRD4 Protein Inhibitors – Pipeline Insight, 2022,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in BRD4 Protein Inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
BRD4 Protein Inhibitors: Overview
Bromodomain-containing protein 4 (BRD4) is an epigenetic reader that recognizes histone proteins and acts as a transcriptional regulator to trigger tumor growth and the inflammatory response. The pan-bromodomain and extra-terminal domain (BET) inhibitor, (+)-JQ1 (1), was reported to inhibit angiogenesis. A number of Brd4 degraders have been reported and showed more efficient anticancer activities than just protein inhibition. The findings on the novel BRD4 inhibitor suggests that, in addition to being a powerful pharmacological tool for further elucidating the roles and functions of BRD4 and its BD domains in angiogenesis, it may also serve as a potential therapeutic strategy for targeting the vasculature in various angiogenesis-dysregulated human diseases. Inactivating Brd4 or downregulating its expression inhibits cancer development, leading to the current interest in Brd4 as a promising anticancer drug target. Numerous Brd4 inhibitors have been studied in recent years and some of them are currently in various phases of clinical trials.
"BRD4 Protein Inhibitors - Pipeline Insight, 2022" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the BRD4 Protein Inhibitors pipeline landscape is provided which includes the disease overview and BRD4 Protein Inhibitors treatment guidelines. The assessment part of the report embraces, in depth BRD4 Protein Inhibitors commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, BRD4 Protein Inhibitors collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
The companies and academics are working to assess challenges and seek opportunities that could influence BRD4 Protein Inhibitors R&D. The therapies under development are focused on novel approaches to treat/improve BRD4 Protein Inhibitors.
This segment of the BRD4 Protein Inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
BRD4 Protein Inhibitors Emerging Drugs
PLX2853: Plexxikon
An orally bioavailable inhibitor of the bromodomain-containing protein 4 (BRD4), with potential antineoplastic activity. Upon oral administration, the BRD4 inhibitor PLX2853 binds to the acetylated lysine recognition motifs in the bromodomain of the BRD4 protein, thereby preventing the binding of BRD4 to acetylated lysines on histones. This disrupts chromatin remodeling and dyregulates gene expression. This may lead to the downregulation of the expression of certain growth-promoting genes, which may induce apoptosis and inhibit the proliferation of BRD4-overexpressing tumor cells. It is currently being evaluated in Phase I/II clinical trial to treat Advanced Malignancies.
Further product details are provided in the report……..
This segment of the report provides insights about the different BRD4 Protein Inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
There are approx. 5+ key companies which are developing the therapies for BRD4 Protein Inhibitors. The companies which have their BRD4 Protein Inhibitors drug candidates in the most advanced stage, i.e. phase I/II include Plexxikon.
DelveInsight’s report covers around 5+ products under different phases of clinical development like
BRD4 Protein Inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Products have been categorized under various Molecule types such as
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses BRD4 Protein Inhibitors therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging BRD4 Protein Inhibitors drugs.
Current Treatment Scenario and Emerging Therapies:
Introduction
Executive Summary
BRD4 Protein Inhibitors: Overview
Pipeline Therapeutics
Therapeutic Assessment
Mid Stage Products (Phase II)
Drug Name: Company Name
Drug profiles in the detailed report…..
Early Stage Products (Phase I/II)
PLX2853: Plexxikon
Drug profiles in the detailed report…..
Inactive Products
BRD4 Protein Inhibitors Key Companies
BRD4 Protein Inhibitors Key Products
BRD4 Protein Inhibitors- Unmet Needs
BRD4 Protein Inhibitors- Market Drivers and Barriers
BRD4 Protein Inhibitors- Future Perspectives and Conclusion
BRD4 Protein Inhibitors Analyst Views
BRD4 Protein Inhibitors Key Companies
Appendix
List of Table
Table 1: Total Products for BRD4 Protein Inhibitor
Table 2: Late Stage Products
Table 3: Mid Stage Products
Table 4: Early Stage Products
Table 5: Pre-clinical & Discovery Stage Products
Table 6: Assessment by Product Type
Table 7: Assessment by Stage and Product Type
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type
Table 12: Inactive Products
List of Figures
Figure 1: Total Products for BRD4 Protein Inhibitor
Figure 2: Late Stage Products
Figure 3: Mid Stage Products
Figure 4: Early Stage Products
Figure 5: Preclinical and Discovery Stage Products
Figure 6: Assessment by Product Type
Figure 7: Assessment by Stage and Product Type
Figure 8: Assessment by Route of Administration
Figure 9: Assessment by Stage and Route of Administration
Figure 10: Assessment by Molecule Type
Figure 11: Assessment by Stage and Molecule Type
Figure 12: Inactive Products
• Kintara Therapeutics
• Phio Pharmaceuticals
• Plexxikon
• CSPC ZhongQi Pharmaceutical Technology
• SignalRx Pharmaceutical
• EPIGeNE Therapeutics
• Sierra Oncology
